Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $164 | $283 | $227 | $696 |
| - Cash | $48 | $60 | $60 | $89 |
| + Debt | $38 | $38 | $38 | $39 |
| Enterprise Value | $153 | $262 | $205 | $645 |
| Revenue | $3 | $4 | $3 | $3 |
| % Growth | -37.2% | 23.8% | 19.9% | – |
| Gross Profit | $1 | $2 | $1 | $1 |
| % Margin | 32% | 37.4% | 27.2% | 46.1% |
| EBITDA | -$32 | -$22 | -$70 | -$45 |
| % Margin | -1,259.3% | -531.7% | -2,124.5% | -1,649.4% |
| Net Income | $29 | -$35 | $44 | -$13 |
| % Margin | 1,123.9% | -852.7% | 1,326.8% | -472.1% |
| EPS Diluted | 0.21 | -0.25 | 0.3 | -0.094 |
| % Growth | 184% | -183.3% | 418.8% | – |
| Operating Cash Flow | -$24 | -$23 | -$30 | -$37 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | -$25 | -$24 | -$31 | -$37 |